SCHEMBL30764764

SCHEMBL30764764

Cc1cccc(CCN2CC3(C2)CN(C(=O)Cc2ccc(Cl)cc2)C3)c1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
POLB P06746 2/20 0.48
HSD11B1 P28845 1/20 0.46
HRH3 Q9Y5N1 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
NLRP3 Q96P20 1/20 0.44
SIGMAR1 Q99720 1/20 0.43
ORAI1 Q96D31 1/20 0.43
CNR1 P21554 1/20 0.42
LMNA P02545 2/20 0.42
HTT P42858 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30764724 0.88 HSD11B1 (0.51) ALDH1A1KDM4EHSD11B1HRH3SMN1; SMN2
SCHEMBL30764754 0.87 HSD11B1 (0.46) HSD11B1SIGMAR1CNR1
SCHEMBL30764743 0.84 MEN1 (0.51) HSD11B1SMN1; SMN2CNR1
SCHEMBL30764710 0.81 HSD11B1 (0.45) ALDH1A1KDM4EPOLBHSD11B1SMN1; SMN2
SCHEMBL30764734 0.81 KMT2A (0.54) POLBHSD11B1
SCHEMBL30764719 0.80 SMN1; SMN2 (0.53) ALDH1A1HSD11B1HRH3SMN1; SMN2SIGMAR1
SCHEMBL30764736 0.79 HSD11B1 (0.49) POLBHSD11B1SIGMAR1
SCHEMBL30764749 0.79 HSD11B1 (0.49) HSD11B1SIGMAR1TP53MAPT
SCHEMBL30764707 0.78 HSD11B1 (0.55) ALDH1A1KDM4EHSD11B1SMN1; SMN2SIGMAR1
SCHEMBL27253461 0.75 MEN1 (0.47) ALDH1A1KDM4EPOLBHRH3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568968-A1 (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Remynd N.V. (BE) 2025-06-18 EP disclosed
WO-2024033479-A1 (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS REMYND N.V. (BE) 2024-02-15 WO disclosed